X4 PHARMACEUTICALS, INC Increase (Decrease) in Contract with Customer, Liability
X4 PHARMACEUTICALS, INC (XFOR) reported Increase (Decrease) in Contract with Customer, Liability of $349.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $408.00K.
- X4 PHARMACEUTICALS, INC increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$59.00K, a 103.26% decline year-over-year.
- X4 PHARMACEUTICALS, INC increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$296.00K.
- X4 PHARMACEUTICALS, INC increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$200.00K.
- X4 PHARMACEUTICALS, INC increase (decrease) in contract with customer, liability for fiscal 2025 was $1.08M.
- X4 PHARMACEUTICALS, INC increase (decrease) in contract with customer, liability for fiscal 2024 was $0.00.
- X4 PHARMACEUTICALS, INC increase (decrease) in contract with customer, liability for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $408.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $349.00K 10-Q · filed 2026-08-06 | $53.00K derived: sum of 3 quarters · filed 2026-08-06 | -$147.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$59.00K 10-Q · filed 2026-05-06 | -$355.00K derived: sum of 2 quarters · filed 2026-05-06 | -$555.00K derived: sum of 3 quarters · filed 2026-05-06 | -$784.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$296.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$496.00K derived: sum of 2 quarters · filed 2026-03-17 | -$725.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.08M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$429.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.38M 10-Q · filed 2025-11-05 | $1.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$229.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.58M 10-Q · filed 2026-08-06 | $1.58M derived: sum of 3 quarters · filed 2026-08-06 | $1.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.81M 10-Q · filed 2026-05-06 | $1.81M derived: sum of 2 quarters · filed 2026-05-06 | $1.81M derived: sum of 3 quarters · filed 2026-05-06 | $1.81M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 10-K · filed 2026-03-17 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $0.00 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |